![]() |
It is currently sold as an acidic dry powder which must be reconstituted into a liquid by a care-giver for injection into the patient. Biodel plans to seek FDA approval of this compound under section 505(b)2 of the Federal Food, Drug and Cosmetic Act which governs the review of an NDA for a modified form of a previously approved product.
We are also working with physicians at leading U.S. medical centers to develop a more stable form of glucagon for use in bi-hormonal pumps to enable more aggressive treatment of diabetes with insulin. Bi-hormonal pumps are being developed to replace current insulin pumps and continuous glucose monitoring devices and allow for more effective continuous regulation of blood glucose. We are currently conducting preclinical studies to evaluate this exciting new approach to diabetes management.
